Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October iito 600x60px
Document › Details

Evotec AG. (3/26/18). "Press Release: Evotec Launches INDiGO, a Unique Integrated Drug Development Solution for Accelerating Early Drug Candidates into the Clinic". Hamburg.

Organisations Organisation Evotec AG (FSE: EVT, TecDAX)
  Group Evotec (Group)
  Organisation 2 Aptuit Ltd.
  Group Evotec (Group)
Products Product INDiGO® drug development service
  Product 2 preclinical research
Index term Index term Aptuit–Evotec: investment, 201707–201708 acquisition $300m in cash of Aptuit from Welsh, Carson, Anderson & Stowe
Persons Person Polywka, Mario (Evotec 201201 COO)
  Person 2 Dorigatti, Roberto (Evotec 201803 SVP Integrated Development Programmes)
     


INDIGO(R) is the market leading integrated drug development solution that accelerates drug candidate delivery from candidate selection through to IND submission in typically less than 52 weeks


Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) has launched its accelerated drug development service INDiGO(R). With the launch of INDiGO(R), Evotec's expertise and capabilities are uniquely combined under one roof to deliver better drug candidates to patients faster and more efficiently than standard industry approaches.

INDiGO(R) is a proven development solution that has been successfully executed by Evotec's recent acquisition of Aptuit for several years, who are market leaders in providing high-value integrated drug discovery and development solutions. The INDiGO(R) service has been proven to reduce the time and cost of pre-clinical drug development whilst delivering a high-quality data package for CTA/IND level regulatory filings. Typical INDiGO(R) activities include:

API manufacture, formulation development, clinical supply, safety assessment, DMPK, bioanalysis and biomarkers, and regulatory submission documents preparation.

Evotec's partners benefit from a single, integrated provider for all required functions and capabilities coupled with best-in-class project management and seasoned scientific leadership.

Dr Mario Polywka, Chief Operating Officer, commented: "Evotec's INDiGO(R) delivers to our partners a truly integrated approach to accelerate development of their drug candidates to regulatory submission in the most time- and cost-efficient manner. Our track record and expertise in combing the appropriate scientific knowledge with the right technical processes and project management ensures on time and budget delivery of clinic ready candidates. INDiGO(R) allows our customers to seamlessly transition from candidate selection into the regulatory space and to patients efficiently and quickly."

Dr Roberto Dorigatti, Senior Vice President, Integrated Development Programmes, said: "Our INDiGO(R) is a truly integrated drug development solution. It is unique in the industry and has a proven track record of success in dramatically reducing (by more than 50%) time and costs during the IND-enabling phase of development and never compromising quality and scientific integrity. Our experienced team understands drug development and not only executes projects but proactively contributes to the science and strategy to expedite new medicines to the market."

For further information on INDiGO(R) and integrated development, please use the following links to a development e-book, an electronic facilities tour, and a talking head:

Facility tour - http://bit.ly/Evotec-indigo-facility_tour
E-book - http://bit.ly/Evotec-Indigo-ebook
Talking Head - http://bit.ly/Evotec-Indigo-Rob_Dorigatti


About Evotec AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. For additional information please go to www.evotec.com and follow us on Twitter @EvotecAG.


FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.


Contact Evotec AG:

Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

   
Record changed: 2018-03-31

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x80px

More documents for Evotec (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px




» top